Fulgent Genetics Q4 revenue misses; forecasts about $350 mln in 2026 revenue

Fulgent Genetics

27/02/2026 12:13

Overview

Genetic testing firm's Q4 revenue grew 9% yr/yr, missing analyst expectations

Adjusted EBITDA loss for Q4 missed analyst expectations

Company reported GAAP loss of $23.4 mln, non-GAAP income of $5.2 mln

Outlook

Fulgent expects 2026 revenue of approximately $350 mln

Company anticipates 2026 non-GAAP loss of approximately ($1.45) per share

Fulgent projects cash and investments of approximately $685 mln by end of 2026

Result Drivers

LABORATORY SERVICES - Growth driven by momentum in laboratory services and investments in AI and digital pathology

THERAPEUTIC DEVELOPMENT - Progress in therapeutic pipeline with FID-007 in Phase 2 and FID-022 in Phase 1

OPERATIONAL EFFICIENCIES - Margin improvements due to streamlined operations and enhanced efficiencies

Company press release: ID:nBw5HmR8na

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$83.34 mln
$85.38 mln (3 Analysts)
Q4 Adjusted EBITDA
Miss
-$4.50 mln
$169,670 (3 Analysts)
Q4 Pretax Profit
Miss
-$29.27 mln
$2.16 mln (2 Analysts)
Q4 Gross Profit
$32.58 mln
Q4 Operating Expenses
$68.82 mln
Q4 Operating Income
-$36.24 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Fulgent Genetics Inc is $35.00, about 41.4% above its February 26 closing price of $24.76

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)